Brivudine is a nucleoside analogue effective in vitro against herpes simplex virus type 1 and varicella-zoster virus. It is given orally in the treatment of herpes zoster in a dose of 125 mg daily for 7 days. It has also been given orally for herpes simplex infection and has been used topically. Brivudine is not currently available in the UK.